Enhancing the Efficacy of Stem Cell Therapy with Glycosaminoglycans.
AuthorLing, L; Ren, X; Cao, X; Hassan, ABM; Mah, S; Sathiyanathan, P; Smith, RAA; Tan, CLL; Eio, M; Samsonraj, RM; ...
Source TitleStem Cell Reports
University of Melbourne Author/sMah, Sophia Ying Yii
AffiliationMedicine Dentistry & Health Sciences
Document TypeJournal Article
CitationsLing, L., Ren, X., Cao, X., Hassan, A. B. M., Mah, S., Sathiyanathan, P., Smith, R. A. A., Tan, C. L. L., Eio, M., Samsonraj, R. M., van Wijnen, A. J., Raghunath, M., Nurcombe, V., Hui, J. H. & Cool, S. M. (2020). Enhancing the Efficacy of Stem Cell Therapy with Glycosaminoglycans.. Stem Cell Reports, 14 (1), pp.105-121. https://doi.org/10.1016/j.stemcr.2019.12.003.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962655
Human mesenchymal stem cell (hMSC) therapy offers significant potential for osteochondral regeneration. Such applications require their ex vivo expansion in media frequently supplemented with fibroblast growth factor 2 (FGF2). Particular heparan sulfate (HS) fractions stabilize FGF2-FGF receptor complexes. We show that an FGF2-binding HS variant (HS8) accelerates the expansion of freshly isolated bone marrow hMSCs without compromising their naivety. Importantly, the repair of osteochondral defects in both rats and pigs is improved after treatment with HS8-supplemented hMSCs (MSCHS8), when assessed histologically, biomechanically, or by MRI. Thus, supplementing hMSC culture media with an HS variant that targets endogenously produced FGF2 allows the elimination of exogenous growth factors that may adversely affect their therapeutic potency.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References